Search

Cerebral blood flow (CBF) was measured before and after i.v. injection of the cerebral vasodilator 10-methoxy-1,6-dimethyl-ergoline-8 beta-methanol-(5-bromonicotinate) (nicergoline, Sermion) in 13 patients with cerebrovascular disease. CBF increased in seven. The possibility is discussed that the effect of the drug in the other patients may have been masked by a fall of CBF which occurs during sequential measurement of patients at rest. Nicergoline is an alpha-adrenergic receptor blocking agent which affects cerebral blood flow by reducing cerebrovascular resistance. The present study was undertaken to assess the acute effect of the drug on cerebral blood flow and blood pressure in patients with cerebrovascular diseases.

Referring to literature and our own cases (140.048 CT investigations--37% of them after intravenous application of contrast media) the possibility of decrease in consequence of contrast application is discussed.